Armistice Capital Among Incyte’s Institutional Holders as $1.25 Billion Vega Acquisition Carries It Into Bleeding Disorders
Incyte agreed on June 8 to acquire Vega Therapeutics for $1.25 billion upfront, a move that carries its hematology franchise into bleeding disorders. Armistice Capital is one of the institutional…